[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lower-urinary-tract-obstructive-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lower-urinary-tract-obstructive-syndrome":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,78,104,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100307401","fetal-cystoscopy-for-severe-lower-urinary-tract-obstruction-100307401",false,"NCT03281798","Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction","Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO): A Prospective Trial","CYSTO","Inclusion Criteria:\n\n1. Pregnant women\n2. Singleton pregnancy\n3. Maternal age ≥ 18 years\n4. Male fetus with LUTO, dilated bladder, \"keyhole sign\" and bilateral hydronephrosis\n5. Oligohydramnios or Anhydramnios\n6. Favorable urine analysis defined as urinary sodium is \\\u003C 100 milliequivalents per liter (mEq\u002FL), chloride \\\u003C 90 mEq\u002FL, and osmolality \\\u003C 200 milliosmoles per kilogram (mOsm\u002Fkg) after 20 weeks and in the absence of previous in utero intervention for the disease (vesicoamniotic shunt placement or fetal cystoscopy).\n7. Absence of chromosomal abnormalities and associated anomalies\n8. Gestational age at the time of the procedure will be between 16 0\u002F7 weeks and 25 6\u002F7 weeks\n9. Normal karyotype by invasive testing (amniocentesis or Chorionic Villus Sampling (CVS)). Patients declining invasive testing will be excluded.\n10. Family have considered and declined the option of termination of the pregnancy at less than 24 weeks.\n11. Family meets psychosocial criteria, including sufficient social support and ability to understand requirements of the study.\n12. Parents or guardian are willing to provide signed informed consent.\n\nExclusion Criteria:\n\n1. Fetal anomaly unrelated to LUTO\n2. Congenital cardiac anomaly\n3. Female fetus\n4. Increased risk for preterm labor including short cervical length (\\\u003C1.5 cm), history of incompetent cervix with or without cerclage, and previous preterm birth\n5. Placental abnormalities (previa, abruption, accreta) known at time of enrollment\n6. Contraindications to surgery including previous hysterotomy in active uterine segment\n7. Technical limitations precluding fetoscopic surgery, such as uterine fibroids, fetal membrane separation, uterine anomalies incompatible with fetoscopy\n8. Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy\n9. Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment\n10. Maternal medical condition that is a contraindication to surgery or anesthesia\n11. Patient does not have health insurance to cover routine clinical care including prenatal care, prenatal ultrasound, amniocentesis, tocolysis, admission, delivery, and fetal vesico-amniotic shunting. The exception will be fetal cystoscopy which is considered an experimental procedure.\n12. Inability to comply with travel and follow-up requirements of the trial\n13. Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy\n14. Patients declining invasive testing\n15. Family does not meet psychosocial criteria including insufficient","FEMALE","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of the study is to study the outcomes of maternal and fetal patients who are undergoing fetal intervention for severe isolated lower urinary tract obstruction (LUTO).",[27,28,29,30],"Lower Urinary Tract Obstructive Syndrome","Lower Urinary Tract Obstruction, Congenital","Bladder Outlet Obstruction","Bladder Outflow Obstruction","RECRUITING","2026-02-20",{"date":34,"type":35},"2026-02-24","ACTUAL",{"date":37,"type":35},"2018-01-01",{"date":39,"type":21},"2028-08-01",{"name":41,"class":42},"Rodrigo Ruano","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100341284","phase-1-serial-amnioinfusions-as-regenerative-therapy-for-pulmonary-hypoplasia-100341284","NCT03723564","Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia","Serial Amnioinfusions as Regenerative Therapy for Pulmonary Hypoplasia in Fetuses With Intrauterine Renal Failure or Severe Renal Anomalies- a Feasibility Study","Inclusion Criteria:\n\n* Pregnant women with singleton uterine pregnancy\n* Maternal age \\> age 18\n* Fetus \\\u003C 26 weeks gestational age with severe LUTO and intrauterine renal failure\n* Fetus \\\u003C 26 weeks gestational age with bilateral renal agenesis\n* Fetus with absence of chromosome abnormalities\n* Fetus with absence of associated anomalies\n* Mother has negative Hepatitis B, Hepatitis C, and HIV testing\n* Mother meets psychosocial criteria that allows her to make a conscious decision about her fetus\u002Finfant\n\nExclusion Criteria:\n\n* Associated fetal anomaly unrelated to LUTO or renal agenesis\n* Increased risk for preterm labor including short cervical length, history of incompetent cervix with or without cerclage, and previous preterm birth\n* Placental abnormalities known at time of enrollment\n* Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy\n* Maternal medical condition that is a contraindication to surgery or anesthesia\n* Mother has declined invasive testing\n* Inability to comply with the travel and follow-up requirements of the trial\n* Participation in another interventional study that influences maternal and fetal morbidity and mortality\n* Participation in this clinical trial during a previous pregnancy","ALL",{"count":53,"type":21},40,[55],"PHASE1","Congenital lower urinary tract obstruction (LUTO) is a heterogeneous group of congenital anomalies that lead bladder outlet obstruction. If a complete obstruction is present, the perinatal mortality is estimated to be as high as 90% because of severe pulmonary hypoplasia due to the lack of amniotic fluid. Survivors have significant risk of renal impairment (90%) requiring dialysis or renal transplantation if no fetal intervention is performed.\n\nRenal agenesis is the congenital absence of one or both kidneys due to complete failure of the kidney to form. As many as 33% of fetuses with bilateral renal agenesis are stillborn, and the rest of them die immediately after birth due to severe pulmonary hypoplasia.\n\nThe objective of the serial amnioinfusions for fetuses with these conditions will be to reduce the severity of pulmonary hypoplasia (regenerating the lung functionality) and therefore increase the chance that the newborn survives to begin peritoneal dialysis. Although there is initial evidence that serial amnioinfusions are feasible for the pregnant women and the fetuses, there is still a need to have a prospective clinical trial to confirm the hypothesis that serial amnioinfusions could prevent severe pulmonary hypoplasia allowing the newborns with bilateral renal agenesis or severe LUTO to survive to begin peritoneal dialysis.\n\nTherefore, the investigators aim to study the hypothesis that serial amnioinfusions for fetuses with severe LUTO and renal failure and those with bilateral renal agenesis will reduce the severity of pulmonary hypoplasia and therefore increase the chance that the newborn survives to begin peritoneal dialysis.",[58,59,60,27],"Renal Failure Congenital","Congenital Renal Anomaly Nos","Renal Agenesis and Dysgenesis",[62,63,64,65,66,67],"bilateral renal agenesis","lower urinary tract obstruction","congenital renal anomalies","fetal surgery","amnioinfusion","fetus","2025-11-08",{"date":70,"type":35},"2025-11-12",{"date":72,"type":35},"2018-10-01",{"date":74,"type":21},"2027-12-31",{"name":76,"class":42},"Mayo Clinic",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":77},"100536491","association-of-urine-bdnf-and-ngf-with-lower-urinary-system-parameters-100536491","NCT06265519","Association of Urine BDNF and NGF With Lower Urinary System Parameters","The Association of Urinary BDNF and NGF With Lower Urinary System Parameters in Patients With Bladder Outlet Obstruction Secondary to Benign Prostate Hyperplasia","Inclusion Criteria:\n\n1. 50-80 years Male\n2. Patients with bladder outlet obstruction secondary to benign prostate hyperplasia\n\nExclusion Criteria:\n\n1. Known neurological disease\n2. Diabetes\n3. Urinary tract infection\n4. Previous prostate surgery\n5. Spinal Cord Trauma\n\n7-Bladder stone 8-Cerebrovascular disease 9-Chronic Renal Failure 10-Ureteral stenosis",true,"MALE","50 Years","80 Years",{"count":90,"type":21},70,[24],"Histologically, BPH is a benign proliferative process involving both epithelial and stromal elements and is characterised by progressive enlargement of the prostate. Symptom complex including increased frequency of urination, sudden feeling of urge to urinate, nocturia, difficulty in urinating, feeling of incomplete emptying of the bladder, decreased flow rate and intermittent urination are called lower urinary tract symptoms (LUTS). The most important cause of LUTS in men is BPH. Many structural and physiological changes occur in the lower urinary system with bladder outlet obstruction. Detrusor hypertrophy and bladder hyperactivity may occur due to bladder outlet obstruction. Although the density of afferent and efferent nerves in the bladder decreases after urethral obstruction, enlargement of their trunks indicates that changes occur in these nerves. In addition, changes also occur in the neural pathways of the central nervous system following lower urinary tract obstruction. Nerve growth factor (NGF) and brain derived neurotropin factor (BDNF) are trophic proteins that act as retrograde messengers between peripheral effector tissue and the nerves that innervate it. In peripheral tissues, the source of NGF and BDNF is presumed to be the target tissues innervated by nerves. Smooth muscle cells, fibroblasts, astrocytes and other cells synthesise NGF and BDNF in culture medium. Many potential stimuli that increase NGF in the lower urinary system have been identified. These are denervation, inflammation and mechanical tension. This information has led to the idea that autonomic innervation changes in the bladder may be related with changing NGF levels. Altered afferent and adrenergic innervation in the obstructed bladder increases the possibility that NGF plays an important role in this neural growth because this type of nerves are highly sensitive to this neurotrophin.\n\nIn this study, we investigated NGF ve BDNF levels in urine samples obtained before surgery (Transurethral Prostate Resection, Prostate Enucleation with Holmium Laser and Prostate Enucleation with Thulium Fibre Laser) and after removal of obstruction in patients with bladder outlet obstruction secondary to benign prostatic enlargement using ELISA method, We aimed to determine the role of NGF and BDNF in bladder outlet obstruction and bladder changes secondary to obstruction by comparing with control patients without obstruction.",[94,27],"Benign Prostatic Hyperplasia With Outflow Obstruction","2025-08-18",{"date":97,"type":35},"2025-08-22",{"date":99,"type":35},"2024-02-01",{"date":101,"type":21},"2026-07-01",{"name":103,"class":42},"Marmara University",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":113,"conditions":114,"keywords":123,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":77},"100572051","amnioinfusion-for-fetal-renal-failure-100572051","NCT06728228","Amnioinfusion for Fetal Renal Failure","Inclusion criteria:\n\n1. Confirmed anhydramnios before 22 weeks GA for patients with FRF.\n2. Consent is signed and first therapeutic amnioinfusion can and does occur before 28 weeks and 6\u002F7 days GA.\n3. Confirmation that the expectant mother understands her options for management of the pregnancy.\n4. Age ≥18 years of age.\n5. Willingness to be followed by the Fetal Care Center at Dallas and deliver at Medical City Dallas.\n6. Willingness for postnatal care to be performed at Medical City Dallas Hospital\u002Fthe Fetal Care Center until maternal discharge.\n7. Consults with Pediatric Nephrology, Neonatology, Transplant Surgery, Pediatric surgery, Maternal-Fetal Medicine Specialist, and a Genetic Counselor.\n\nExclusion criteria:\n\n1. Cervix less than 2.5 cm in length.\n2. No fatal findings on Karyotype (e.g trisomy 13, or 18) or Microarray fatal findings excluding those that are related to pulmonary hypoplasia due to fetal renal failure (e.g. Meckel-Gruber, PCKD).\n3. Other significant congenital anomalies in the fetus.\n4. Evidence of chorioamnionitis or abruptio placentae.\n5. Evidence of rupture of membranes or chorionic-amniotic separation.\n6. Evidence of preterm labor.\n7. Multiple gestation.\n8. Severe maternal medical condition in pregnancy.\n9. Clinically diagnosed maternal depression, psychoses, or anxiety that are refractory to treatment.\n10. Technical limitations precluding amnioinfusion.",{"count":111,"type":21},35,[24],"The goal of this clinical trial is to learn if serial amnioinfusions can improve the chances of survival for fetuses with severe kidney problems that cause low amniotic fluid (anhydramnios). Low amniotic fluid can affect lung development and may lead to serious health issues for the fetus. The main questions this study aims to answer are:\n\n* Can serial amnioinfusion increase the chances of survival for these fetuses?\n* Does this procedure improve chances of survival until dialysis and\u002For kidney transplant?\n\nParticipants will:\n\n* Receive regular amnioinfusions, which is a procedure that adds fluid to the amniotic cavity.\n* Undergo monitoring to check the effects on the fetus and mother.\n\nThis study will help researchers understand if amnioinfusion is a useful treatment for fetal kidney problems and may provide valuable information for similar cases in the future.",[115,116,117,118,119,120,121,27,122],"Multicystic Dysplastic Kidney","Polycystic Kidney Disease","Fetal Renal Anomaly","Anhydramnios","Potter Syndrome","Lung Hypoplasia","Multicystic Renal Dysplasia, Bilateral","Bilateral Renal Agenesis",[124,125,126,127],"Fetal Renal Failure","Kidney Disease","MCDK","PCKD","2024-12-18",{"date":130,"type":35},"2024-12-20",{"date":132,"type":35},"2024-12-05",{"date":134,"type":21},"2026-11-15",{"name":136,"class":137},"Fetal Care Center, PLLC","INDUSTRY",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":86,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":155,"overallStatus":163,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100550888","eep-in-patients-with-urodynamically-proven-duda-100550888","NCT06452927","EEP in Patients With Urodynamically Proven DU\u002FDA","Endoscopic Enucleation of the Prostate in Patients With Urodynamically Proven Detrusor Underactivity\u002FAcontractility","Inclusion Criteria:\n\n* Endoscopic enucleation of the prostate in patients with DU\u002FDA secondary to a non-neurogenic aetiology:\n\n  * Detrusor underactivity (DU) defined urodynamically as a bladder contractility index (BCI) of \\\u003C100.\n  * Detrusor acontractility (DA) defined urodynamically as the absence of a detrusor contraction despite filling to bladder capacity.\n\nExclusion Criteria:\n\n* Neurogenic aetiology for DU\u002FDA (Parkinson, stroke…)\n* Other surgical approaches for the treatment of benign prostate hyperplasia (Aquaablation, open enucleation of the prostate, open prostatectomy, transurethral resection of the prostate...)","40 Years",{"count":147,"type":21},300,[24],"The aim of this project is to create und evaluate a multicentral, retro-\u002Fprospective database for patients with urodynamically proven detrusor underactivity (DU) or acontractility (DA) secondary to a non-neurogenic aetiology, who undergo endoscopic, anatomic enucleation of the prostate (EEP).",[151,27,152,153,154],"Lower Urinary Tract Symptoms","Detrusor Underactivity","Detrusor Areflexia","Prostatic Hyperplasia",[156,157,158,152,159,160,161,162],"Endoscopic Enucleation of the Prostate","BipoEP","ThuLEP","Detrusor Acontractility","HoLEP","Urodynamics","Pressure Flow Study","NOT_YET_RECRUITING","2024-06-06",{"date":166,"type":35},"2024-06-11",{"date":168,"type":21},"2024-09",{"date":170,"type":21},"2028-09",{"name":172,"class":173},"EEPiDuDa Study Group","NETWORK"]